Live Breaking News & Updates on Aduro Biotech

Stay updated with breaking news from Aduro biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Erdafitinib Exhibits Activity in Intermediate-Risk NMIBC With FGFR3 Mutations

Erdafitinib produced responses in 94% of patients with intermediate-risk, FGFR3-mutant NMIBC in the phase 2 THOR-2 trial. Erdafitinib produced responses in 94% of patients with intermediate-risk, FGFR3-mutant NMIBC in the phase 2 THOR-2 trial. ....

Society Of Urologic Oncology Annual Meeting , Janssen Research Development , Bristol Myers Squibb , Urologic Oncology Annual Meeting , Janssen Research , Pacific Edge , Aduro Biotech ,